Brainstorm Cell Therapeutics Inc
BCLI1.170USD
-0.030-2.50%
交易中 （美东）报价延迟15分钟
9.26M总市值
亏损市盈率 TTM
关于 Brainstorm Cell Therapeutics Inc 公司
BrainStorm Cell Therapeutics Inc. 是一家自体成人干细胞疗法开发商，用于治疗衰弱性神经退行性疾病。神经退行性疾病包括肌萎缩侧索硬化症 (ALS)、进行性多发性硬化症 (PMS)、阿尔茨海默病 (AD) 等。该公司从事 NurOwn 技术平台的临床开发和商业化，该平台用于生产自体间充质干细胞-神经营养因子 (MSC-NTF) 细胞。NurOwn 利用细胞培养方法诱导自体骨髓衍生的 MSC 分泌高水平 NTF，调节神经炎症和神经退行性疾病过程，促进神经元存活并改善神经功能。自体 MSC-NTF 细胞用于治疗 ALS。该公司已完成 ALS 的 III 期试验。其全资子公司 BrainStorm Cell Therapeutics Ltd. 拥有将 NurOwn 技术商业化的独家权利。
公司简介
公司代码BCLI
公司名称Brainstorm Cell Therapeutics Inc
上市日期May 28, 2003
CEOMr. Chaim Lebovits
员工数量27
证券类型Ordinary Share
年结日May 28
公司地址1325 Avenue Of Americas
城市NEW YORK
上市交易所US 'Other OTC' and Grey Market
国家United States of America
邮编10019
电话12014880460
网址https://brainstorm-cell.com/
公司代码BCLI
上市日期May 28, 2003
CEOMr. Chaim Lebovits
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Uri Yablonka
Mr. Uri Yablonka
Director, Executive Vice President, Chief Business Officer, Secretary
Director, Executive Vice President, Chief Business Officer, Secretary
68.46K
--
Dr. Hartoun Hartounian, Ph.D.
Dr. Hartoun Hartounian, Ph.D.
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
52.00K
--
Ms. Alla Patlis, CPA
Ms. Alla Patlis, CPA
Interim Chief Financial Officer, Controller
Interim Chief Financial Officer, Controller
44.35K
+919.54%
Dr. Irit Arbel, Ph.D.
Dr. Irit Arbel, Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
41.05K
--
Mr. Nir Naor, CPA
Mr. Nir Naor, CPA
Independent Director
Independent Director
31.47K
+3833.25%
Dr. Ibrahim B. (Bob) Dagher, M.D.
Dr. Ibrahim B. (Bob) Dagher, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
Director
Director
--
--
Prof. Jacob A. Frenkel, Ph.D.
Prof. Jacob A. Frenkel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Menghisteab (Menghis) Bairu, M.D.
Dr. Menghisteab (Menghis) Bairu, M.D.
Independent Director
Independent Director
--
--
Dr. Anthony John (Tony) Polverino, Ph.D.
Dr. Anthony John (Tony) Polverino, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Uri Yablonka
Mr. Uri Yablonka
Director, Executive Vice President, Chief Business Officer, Secretary
Director, Executive Vice President, Chief Business Officer, Secretary
68.46K
--
Dr. Hartoun Hartounian, Ph.D.
Dr. Hartoun Hartounian, Ph.D.
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
52.00K
--
Ms. Alla Patlis, CPA
Ms. Alla Patlis, CPA
Interim Chief Financial Officer, Controller
Interim Chief Financial Officer, Controller
44.35K
+919.54%
Dr. Irit Arbel, Ph.D.
Dr. Irit Arbel, Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
41.05K
--
Mr. Nir Naor, CPA
Mr. Nir Naor, CPA
Independent Director
Independent Director
31.47K
+3833.25%
Dr. Ibrahim B. (Bob) Dagher, M.D.
Dr. Ibrahim B. (Bob) Dagher, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月27日 周日
更新时间: 7月27日 周日
持股股东
股东类型
持股股东
持股股东
占比
Armistice Capital LLC
8.70%
Ruck (Matthew J)
3.47%
Ness (Kevin Dean)
2.57%
Lebovits Chaim
2.53%
Caldwell Sutter Capital, Inc
1.98%
Other
80.75%
持股股东
持股股东
占比
Armistice Capital LLC
8.70%
Ruck (Matthew J)
3.47%
Ness (Kevin Dean)
2.57%
Lebovits Chaim
2.53%
Caldwell Sutter Capital, Inc
1.98%
Other
80.75%
股东类型
持股股东
占比
Individual Investor
14.30%
Hedge Fund
9.03%
Investment Advisor
3.58%
Holding Company
1.68%
Investment Advisor/Hedge Fund
0.73%
Research Firm
0.04%
Other
70.63%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
115
2.33M
29.37%
+771.43K
2025Q1
116
2.29M
28.90%
+743.86K
2024Q4
114
1.19M
21.02%
-226.10K
2024Q3
109
1.22M
22.61%
-265.31K
2024Q2
109
1.32M
25.54%
+439.02K
2024Q1
108
855.32K
19.26%
-132.87K
2023Q4
109
841.70K
26.44%
-125.02K
2023Q3
116
902.82K
33.14%
-178.28K
2023Q2
123
1.03M
39.20%
+17.38K
2023Q1
150
979.29K
38.21%
+5.81K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Armistice Capital LLC
690.67K
8.7%
+690.67K
--
Mar 31, 2025
Ruck (Matthew J)
275.84K
3.47%
+275.84K
--
Nov 13, 2024
Ness (Kevin Dean)
204.00K
2.57%
-40.00K
-16.39%
Feb 14, 2024
Lebovits Chaim
200.96K
2.53%
--
--
Apr 01, 2025
Caldwell Sutter Capital, Inc
157.01K
1.98%
--
--
Mar 31, 2025
ACC International Holdings, Ltd.
133.39K
1.68%
--
--
Apr 01, 2025
Dagher (Ibrahim B.)
79.52K
1%
--
--
Apr 01, 2025
Yablonka (Uri)
68.46K
0.86%
--
--
Apr 01, 2025
Geode Capital Management, L.L.C.
58.16K
0.73%
+5.66K
+10.79%
Mar 31, 2025
Hartounian (Hartoun)
52.00K
0.66%
--
--
Apr 01, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Sep 26, 2024
Merger
15<1
Sep 26, 2024
Merger
15<1
Sep 26, 2024
Merger
15<1
Sep 26, 2024
Merger
15<1
公告日期
类型
比率
Sep 26, 2024
Merger
15<1
Sep 26, 2024
Merger
15<1
Sep 26, 2024
Merger
15<1
Sep 26, 2024
Merger
15<1
